+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Preclinical Brain Imaging Market, By Imaging Type, By End User, Estimation & Forecast, 2017-2030

  • PDF Icon

    Report

  • 124 Pages
  • December 2022
  • Region: Global
  • Astute Analytica
  • ID: 5739167

Global preclinical brain imaging market is projected to grow at a CAGR of 5.78% during the forecast period 2017-2030

The global preclinical brain imaging market held a market value of USD 658.70 million in 2021 and is likely to reach USD 1,076.21 million by the year 2030. The market is anticipated to register a CAGR of 5.78% during the forecast period.

Only a small number of the various imaging modalities used in preclinical imaging are appropriate for imaging tiny animals, while others can be utilised to image large animals. Researchers employ preclinical imaging to visualise changes in the molecular, tissue, and organ systems of animals.

A technique for scanning and visualising neurological activity all through preclinical research is called preclinical brain imaging. Structured imaging and functional imaging are the two subcategories of preclinical brain imaging. Functional imaging is mostly used to diagnose metabolic problems, while structural brain imaging checks the structure of massive intracranial organs.

The market is expanding primarily as a result of an increase in investments and financing for R&D as well as the rapid pace of technological improvements that have led to the creation of hybrid imaging systems. Preclinical research is changing the way that modern medicine is practised and how health issues are addressed. Preclinical imaging techniques fully adhere to 3R (Replacement, Reduction, and Refinement) policies and allow for the reduction of biological variability, the acquisition of an impressive amount of distinct information, and a significant reduction in the number of animals needed for a given study.

Technology developments in molecular imaging, rising need for non-invasive small animal imaging techniques, and an increase in preclinical research funding from both commercial and public organisations are the main drivers driving the growth of the preclinical brain imaging market.

Growth Influencers:

Rising Awareness on Early Diagnosis

A new wave of diagnostics has replaced conventional diagnostics, marking a paradigm shift. The market under investigation is expected to develop as more products with cutting-edge features are introduced. For instance, the African Society for Laboratory Medicine (ASLM) and the Africa Centers for Disease Control and Prevention have teamed up to launch the Africa Collaborative Initiative to Advance Diagnostics in order to overcome the current barriers preventing the advancement of the diagnostic agenda in Africa (AFCAD). This strategic alliance was introduced in December 2018 in Abuja to advance the achievement of universal healthcare in Africa.

Additional collaborators in this effort include UNITAID, Institut de Recherche, de Surveillance Epidémiologique et de Formation (IRESSEF), African Field Epidemiology Network (AFENET), World Health Organization Africa Regional Office (WHO-AFRO), and the Clinton Health Access Initiative (CHAI). Over the past ten years, significant expenditures have been made by national governments, NGOs, partners, and donors to address the technical, financial, and health system causes of diagnostic gaps in Africa.

The surge in population growth

The high rate of population expansion directly adds to the rising need for preclinical brain imaging. For instance, the population of the globe is projected to rise by 2 billion people in the next 30 years, from 7.7 billion people today to 9.7 billion in 2050, with a potential peak of 11 billion people by 2100, according to statistics provided by the United Nations. As a result, the market is expanding due to the strong demand that the rising population generates.

Segments Overview:

The global preclinical brain imaging market is segmented into imaging type and end user.

By Imaging Type

Computed Tomography (CT)

Magnetic Resonance Imaging (MRi)

Positron Emission Tomography (PET)

Single Photon Emission Computed Tomography (SPECT)

The computed tomography segment held the highest share of more than 60% in 2021.

By End User

Pharma and Biotech Companies

Contract research organization (CRO’s)

Education & Research Institutes

The pharma and biotech companies segment is expected to reach USD 531.16 million by 2030.

Regional Overview

By region, the global preclinical brain imaging market is divided into Europe, North America, Asia Pacific, Middle East & Africa, and South America.

The North American market for preclinical brain imaging held the largest market share of more than 35% in 2021. Moreover, the Asia Pacific market for preclinical brain imaging is expected to grow highest at a CAGR of 6.51% over the forecast period.

Competitive Landscape

Key players operating in the global preclinical brain imaging market include Acadia Healthcare, The MENTOR Network, Universal Health Services, Inc., Behavioral Health Network, Inc., CareTech Holdings PLC, Ascension Seton, Pyramid Healthcare, and Promises Behavioral Health, among others.

The major players in the market hold approximately 45% of the market share. The players are focused on mergers, new product launches, and partnerships. For instance, for its array of market-leading preclinical magnetic resonance imaging (MRI) equipment, Bruker introduced cutting-edge 7 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets in May 2022. Moreover, PerkinElmer announced in April 2022 that the Vega imaging system, a first-of-its-kind ultrasound platform that integrates hands-free, automated technology well with high-throughput capability to expedite non-invasive research and drug development studies of liver, cancer, as well as kidney disease, cardiology, and more, had been added to its in vivo imaging portfolio.

The global preclinical brain imaging market report provides insights on the below pointers:

Market Penetration: Provides comprehensive information on the market offered by the prominent players

Market Development: The report offers detailed information about lucrative emerging markets and analyzes penetration across mature segments of the markets

Market Diversification: Provides in-depth information about untapped geographies, recent developments, and investments

Competitive Landscape Assessment: Mergers & acquisitions, certifications, product launches in the global Preclinical brain imaging market have been provided in this research report. In addition, the report also emphasizes the SWOT analysis of the leading players.

Product Development & Innovation: The report provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

Pricing Analysis: Pricing analysis of various components

Manufacturing Cost Analysis: Cost-share of various components in preclinical brain imaging, cost analysis of preclinical brain imaging tools

The global Preclinical brain imaging market report answers questions such as:

What is the market size and forecast of the global preclinical brain imaging market?

What are the inhibiting factors and impact of COVID-19 on the global preclinical brain imaging market during the assessment period?

Which are the products/segments/applications/areas to invest in over the assessment period in the global preclinical brain imaging market?

What is the competitive strategic window for opportunities in the global preclinical brain imaging market?

What are the technology trends and regulatory frameworks in the global preclinical brain imaging market?

What is the market share of the leading players in the global preclinical brain imaging market?

What modes and strategic moves are considered favorable for entering the global preclinical brain imaging market?

Table of Contents

Chapter 1. Research Framework
1.1 Research Objective
1.2 Product Overview
1.3 Market Segmentation
Chapter 2. Research Methodology
2.1 Qualitative Research
2.1.1 Primary & Secondary Sources
2.2 Quantitative Research
2.2.1 Primary & Secondary Sources
2.3 Breakdown of Primary Research Respondents, By Region
2.4 Assumption for the Study
2.5 Market Size Estimation
2.6. Data Triangulation
Chapter 3. Executive Summary: Global Preclinical Brain Imaging Market
Chapter 4. Global Preclinical Brain Imaging Market Overview
4.1. Industry Value Chain Analysis
4.1.1. OEMs
4.1.2. Service Provider
4.1.3. Supply & Distribution
4.1.4. End-Users
4.2. Industry Outlook
4.3. PESTLE Analysis
4.4. Porter's Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of Substitutes
4.4.4. Threat of New Entrants
4.4.5. Degree of Competition
4.5. Market Dynamics and Trends
4.5.1. Growth Drivers
4.5.2. Restraints
4.5.3. Opportunities
4.5.4. Key Trends
4.6. Covid-19 Impact Assessment on Market Growth Trend
4.7. Market Growth and Outlook
4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2017 - 2030
4.7.2. Price Trend Analysis
4.8. Competition Dashboard
4.8.1. Market Concentration Rate
4.8.2. Company Market Share Analysis (Value %), 2020
4.8.3. Competitor Mapping
Chapter 5. Global Preclinical Brain Imaging Market, By Imaging Type
5.1. Key Insights
5.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
5.2.1. Computed Tomography (CT)
5.2.2. Magnetic Resonance Imaging (MRi)
5.2.3. Positron Emission Tomography (PET)
5.2.4. Single Photon Emission Computed Tomography (SPECT)
Global Preclinical Brain Imaging Market, By End User
5.3. Key Insights
5.4. Market Size and Forecast, 2017 - 2030 (US$ Mn)
5.4.1. Pharma and Biotech Companies
5.4.2. Contract research organization (CRO's)
5.4.3. Education & Research Institutes
Global Preclinical Brain Imaging Market Analysis, By Region
5.5. Key Insights
5.6. Market Size and Forecast, 2017 - 2030 (US$ Mn)
5.6.1. North America
5.6.1.1. The U.S.
5.6.1.2. Canada
5.6.1.3. Mexico
5.6.2. Europe
5.6.2.1. Western Europe
5.6.2.1.1. The UK
5.6.2.1.2. Germany
5.6.2.1.3. France
5.6.2.1.4. Italy
5.6.2.1.5. Spain
5.6.2.1.6. Rest of Western Europe
5.6.2.2. Eastern Europe
5.6.2.2.1. Poland
5.6.2.2.2. Russia
5.6.2.2.3. Rest of Eastern Europe
5.6.3. Asia Pacific
5.6.3.1. China
5.6.3.2. India
5.6.3.3. Japan
5.6.3.4. South Korea
5.6.3.5. Australia & New Zealand
5.6.3.6. ASEAN
5.6.3.7. Rest of Asia Pacific
5.6.4. Middle East & Africa (MEA)
5.6.4.1. UAE
5.6.4.2. Saudi Arabia
5.6.4.3. South Africa
5.6.4.4. Rest of MEA
5.6.5. South America
5.6.5.1. Brazil
5.6.5.2. Argentina
5.6.5.3. Rest of South America
Chapter 6. North America Preclinical Brain Imaging Market Analysis
6.1. Key Insights
6.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
6.2.1. By Imaging Type
6.2.2. By End User
6.2.3. By Country
US Preclinical Brain Imaging Market Analysis
6.3. Key Insights
6.4. Market Size and Forecast, 2017 - 2030 (US$ Mn)
6.4.1. By Imaging Type
6.4.2. By End User
Chapter 7. Europe Preclinical Brain Imaging Market Analysis
7.1. Key Insights
7.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
7.2.1. By Imaging Type
7.2.2. By End User
7.2.3. By Country
Chapter 8. Asia Pacific Preclinical Brain Imaging Market Analysis
8.1. Key Insights
8.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
8.2.1. By Imaging Type
8.2.2. By End User
8.2.3. By Country
Chapter 9. South America Preclinical Brain Imaging Market Analysis
9.1. Key Insights
9.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
9.2.1. By Imaging Type
9.2.2. By End User
9.2.3. By Country
Chapter 10. Middle East & Africa Preclinical Brain Imaging Market Analysis
10.1. Key Insights
10.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
10.2.1. By Imaging Type
10.2.2. By End User
10.2.3. By Country
Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, Measurement Methods and Business Strategy Outlook)
11.1. Acadia Healthcare
11.2. The MENTOR Network
11.3. Universal Health Services, Inc.
11.4. Behavioral Health Network, Inc.
11.5. CareTech Holdings PLC
11.6. Ascension Seton
11.7. Pyramid Healthcare
11.8. Promises Behavioral Health

Executive Summary

The global preclinical brain imaging market is estimated to witness significant growth over the forecast period due to the rising penetration of research activities, increasing device development, discovery and diagnostic studies. The market is boosted by rising geriatric population, and government support. The market is anticipated to reach USD 1,076.21 million by 2030. In addition to that, the key market players are actively involved in strategic collaborations, product development, launches, and mergers & acquisitions. Furthermore, the North American market for preclinical brain imaging held the largest market share owing to the rising strategic activities and increasing clinical trials. The market is segmented based on imaging type and end user.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Acadia Healthcare
  • The MENTOR Network
  • Universal Health Services, Inc.
  • Behavioral Health Network, Inc.
  • CareTech Holdings PLC
  • Ascension Seton
  • Pyramid Healthcare
  • Promises Behavioral Health

Table Information